HIV integrase inhibitors in ART-experienced patients

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 415-421

  Blanco, Jose Luis ^a   Martinez Picado, Javier ^b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

ART experienced; dolutegravir; elvitegravir; HIV 1; integrase inhibitor; raltegravir; simplification strategy

Indexed keywords

CYTOCHROME P450; DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; TIPRANAVIR; VIRUS RNA;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; CLINICAL PRACTICE; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; GENE DOSAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TREATMENT DURATION; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; PYRROLIDINONES; QUINOLONES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84865616153     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356dcb6     Document Type: Review

References (30)

1. Al-Mawsaw LQ, Fikkert V, Dayam R, et al. Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. PNAS 2006; 103:10080-10085.
2. Buzon MJ, Marfil SM, Puertas MC, et al. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antiv Ther 2008; 13:881-893.
3. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007; 369:1262-1269.
4. Gatell JM, Katlama C, Grinsztejn B, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr 2010; 53:456- 463.
5. Steigbigel RT, Cooper DA, Kumar PN, et al. RAL with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354
6. Cooper DA, Steigbigel RT,Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355- 365
7. Teppler H, Brown DD, Leavitt RY, et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res 2011; 9:40-53.
8. Blanco JL, Varghese V, Rhee SY, et al. HIV-1 INIs resistance and its clinical implications. J Infect Dis 2011; 203:1204-1214.
9. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50: 605-612.
10. Rockstroh JK, Teppler H, Zhao, et al. Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS 2011; 25:1365-1369.
11. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: Results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441-1449.
12. Charpentier C, Roquebert B, Colin C, et al. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS 2010; 24:2651-2656.
13. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-dailyintegrase inhibitor, against resistant HIV type 1: Results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010; 201:814-822.
14. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of oncedaily elvitegravir versus twice daily raltegravir in treatment-experienced patientswith HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, noninferiority study. Lancet Infect Dis 2012; 12:27-35
15. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics /pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011; 25:1737-1745.
16. Clotet B, Katlama C, Lalezari J, et al. HIV integrase resistance profiles andS/GSK1349572 baseline phenotypic susceptibility for subjects experiencingvirologic failure on raltegravir (RAL) in the (VIKING study, ING112961). XVIII International HIV Drug Resistance Workshop; June 2010; Dubrovnik,Croatia.
17. Seki T, Kobayashi M, Wakasa-Morimoto C, et al. S/GSK1349572 is a potentnext generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. 17th Conference on Retroviruses and Opportunistic Infections; 2010.
18. Lewin SR, Rouzioux C. HIV cure and eradication: How will we get from the laboratory to effective clinical trails? AIDS 2011; 25:885-887
19. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immunedynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465
20. Llibre JM, Buzón MJ, Massanella, et al. Treatment intensification with raltegravirin subjects with sustained HIV-1 viraemia suppression: A randomized 48-week study. Antivir Ther 2012; 17:355-356.
21. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-2460.
22. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-919.
23. Gandhi RT, Coombs RW, Chan ES, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receivingantiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59:229-235
24. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infectedwith drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195.
25. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor fordrug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
26. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination withan optimized background for antiretrovirals in treatment-experienced HIV-1- infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005; 40:413- 421.
27. De Castro N, Braun J, Charreau I. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: A randomized open-label trial. Clin Infect Dis 2009; 49:1259-1267.
28. Eron JJ, Young B,Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407
29. Marti'nez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavirboosted protease inhibitors in HIV-infected patients: The SPIRAL study. AIDS 2010; 24:1697-1707. In the SPIRAL study, the simplification from booster-protease inhibitor to RAL showed the noninferiority.
30. Blanco JL, Martinez E, Llibre JM, et al. Role of nucleoside backbone activity in virological outcome after switching a ritonavir-boosted protease inhibitor (PI/r) to raltegravir (RAL): A post-hoc analysis of SPIRAL study. XIV International HIV Drug Resistance Workshop; June 2011; Los Cabos, Mexico.